Assembly Biosciences, a biotechnology company based in South San Francisco, develops treatments for chronic hepatitis B and other infectious diseases, with a pipeline including multiple antiviral agents. The company, which went public in December 2010, employs 65 people.
ASMB has been in the news recently: Assembly Biosciences has launched STAGE AI, an AI-powered operating system that enhances campaign relevance and efficiency for clients by 30%. Additionally, Jill Kelly has been appointed as the new CEO of Assembly North America, effective February 3, 2025.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
